Abstract 48P
Background
Modulated electro-hyperthermia (mEHT) is an advanced option in the hyperthermia field, applying a 13.56 MHz radiofrequency electromagnetic current to induce tumor-specific damage. This study investigates the mEHT-induced molecular effect and the potential of combination non-steroid anti-inflammatory drugs (NSAIDs) to enhance its anti-tumor effects in 4T1 triple-negative breast cancer (TNBC) and B16F10 melanoma mouse models.
Methods
4T1 TNBC and B16F10 melanoma cell lines were injected into Balb/C and C57BL/6 mice, respectively. They have been treated according to the protocol with only mEHT or mEHT combined with non-selective COX-inhibitors (Aspirin) or selective COX2 inhibitors (SC236). Tumor volume was monitored by ultrasound and a digital caliper. At the end of the experiments, mice were euthanized and tumors excised for molecular studies.
Results
Here we report that mEHT monotherapy stimulates local IL1-beta and IL6, and consequently cyclooxygenase 2 (COX 2) production. These effects could be considered as part of a self-defensive, wound-healing reaction of the tumor to protect itself from the mEHT-induced stress. In the present study, we combined mEHT with non-steroid anti-inflmmatory drugs (NSAIDs), the non-selective (Aspirin), or the selective COX2 inhibitor (SC236) in vivo. Here we demonstrate that NSAID treatment synergistically increased the effect of mEHT in 4T1 TNBC. Tumor weight and tumor volume (measured by ultrasound and a digital caliper) were lowest, and the tumor destruction ratio (TDR) was the highest in the combination treated (NSAID + mEHT) groups. Tumor damage was accompanied by a significant increase in cleaved caspase-3 (cC3), suggesting an important role for apoptosis. Similarly, in the B16F10 melanoma model, lung nodules were significantly less in mice treated with mEHT + Aspirin.
Conclusions
NSAIDs effectively enhance the mEHT anti-tumor effect in TNBC and melanoma cancer models; they increase tumor destruction, where apoptosis may play a role. Disecting the exact molecular mechanisms further is under our current investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Semmelweis University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
57P - Metastasis organotropism: Unveiling associated proteins using network biology
Presenter: Margarida Carrolo
Session: Poster session 09
59P - Correlation of tumor microenvironment signature in advanced stage non-small cell lung cancer with EGFR mutation who received EGFR-TKIs
Presenter: Chaiyapong Ngamchokwathana
Session: Poster session 09
60P - Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation
Presenter: Xuejin Ou
Session: Poster session 09
61P - Next generation sequencing and its clinical utility in advanced cancer: Single institute experience from low-middle income country
Presenter: Amit Badola
Session: Poster session 09
62P - Prebiotics modulate gut microbiota-mediated T cell immunity to enhance sintilimab inhibition of lung cancer
Presenter: QIN YAN
Session: Poster session 09
63P - Addition of human chorionic gonadotropin to the current standard mobilization approach with granulocyte-colony stimulating factor increases overall survival in a murine model of peripheral blood stem cell transplantation: Are we far enough for therapy?
Presenter: Andrei Cismaru
Session: Poster session 09
64P - Developing novel therapeutics for bladder cancer leveraging drosophila models
Presenter: Takuya Moriguchi
Session: Poster session 09
65P - Ionizing radiation induces vascular smooth muscle cell senescence through activating NF-κB-CTCF-p16 pathway
Presenter: xuefeng zheng
Session: Poster session 09
66P - Exploring the radiobiology and dosimetry of targeted alpha therapy as a tool to optimize its clinical application: A preclinical study
Presenter: Maria Filomena Botelho
Session: Poster session 09
67P - The effect of non-viral gene-immune therapy via OX40L or 4-1BBL on murine subcutaneous CT26 colon cancer model
Presenter: Olga Rakitina
Session: Poster session 09